- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04968184
Wirksamkeit und Sicherheit von KBP-5074 bei unkontrollierter Hypertonie und mittelschwerer oder schwerer CKD (Clarion-CKD)
Eine randomisierte, doppelblinde, placebokontrollierte, multizentrische Phase-3-Studie zur Bewertung der Wirksamkeit und Sicherheit des KBP-5074-Mineralocorticoid-Rezeptor-Antagonisten bei Patienten mit unkontrollierter Hypertonie und mittelschwerer oder schwerer (Stadium 3b/4) CKD
This Phase 3, randomized, Double-blind, placebo-controlled, 2-arm, parallel-group, multicenter study with randomized withdrawal will evaluate the efficacy, safety, and durability of KBP-5074 in adult participants who have stage 3b/4 chronic kidney disease (CKD) (estimated glomerular filtration rate [eGFR] calculated using the Chronic Kidney Disease Epidemiology Collaboration [CKD-EPI] formula [eGFR {EPI}] ≥15 to ≤44 mL/min/1.73 m^2) and uncontrolled hypertension (systolic blood pressure (SBP) ≥140 and <180 mm Hg and taking 2 or more antihypertensive medications.
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Participants in this study will be recruited, screened, and enrolled at approximately 140 study sites globally.
The study will consist of the following periods:
- Pretreatment Phase: This will include prescreening assessment and screening period of up to 4 weeks and 2-week Open-label placebo Run-In period.
- A 24-week Double-blind Treatment Period (Randomization to Week 24) will include: An initial 12-week (Randomization to Week 12) and second 12-week (Week 12 to Week 24) treatment period and a second 12-week treatment period (Week 12 to Week 24), during both the periods study drug will be titrated.
- A 24-week Open-label Treatment Period (Week 24 to Week 48) during which eligible participants will receive Open-label KBP-5074.
- A 4-week Randomized Double-blind Withdrawal Period (Week 48 to Week 52) during which eligible participants will be randomized to continue their current KBP-5074 dose at the end of Open-label treatment or receive matching placebo for 4 weeks.
- A 4-week post-treatment Follow-Up Period (Week 52 to Week 56).
During, 24-week Double-blind Treatment Period, 24-week Open-label Treatment Period, and at 4-week Randomized Double-blind Withdrawal Period, the background antihypertensive medications change may or may not be allowed.
At Double-blind Treatment Period, eligible participants will be randomly assigned in a 1:1 ratio to KBP-5074 0.25 mg or matching placebo once daily (QD).
At the Randomized Double-blind Withdrawal Period, participants who meet the randomized withdrawal criteria will be randomly assigned in a 1:1 ratio to continue their current KBP-5074 dose at the end of the Open-label Treatment Period or matching placebo QD.
The study design included a pre-planned futility determination by an Independent Data Monitoring Committee (IDMC).
The trial was originally sponsored by KBP Biosciences PTE Ltd, but sponsorship was transferred to Novo Nordisk after the trial was terminated following the futility determination by IDMC.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 3
Kontakte und Standorte
Studienorte
-
-
New South Wales
-
Gosford, New South Wales, Australien, 2250
- Renal Research
-
-
South Australia
-
Adelaide, South Australia, Australien, 5000
- Royal Adelaide Hospital
-
-
Victoria
-
Heidelberg, Victoria, Australien, 3084
- Austin Hospital
-
-
-
-
Kanton Sarajevo
-
Sarajevo, Kanton Sarajevo, Bosnien und Herzegowina, 71000
- Clinical Center University of Sarajevo
-
-
Republika Srpska
-
Banja Luka, Republika Srpska, Bosnien und Herzegowina, 78000
- Univerzitetski klinicki centar Republike Srpske - Internal Medicine, Nephrology
-
Foca, Republika Srpska, Bosnien und Herzegowina, 73300
- The University Hospital Foca
-
Gradiska, Republika Srpska, Bosnien und Herzegowina, 78400
- General Hospital Gradiska
-
Trebinje, Republika Srpska, Bosnien und Herzegowina, 89101
- General hospital Trebinje - Gastroenterology
-
-
Zeničko-dobojski Kanton
-
Tešanj, Zeničko-dobojski Kanton, Bosnien und Herzegowina, 72460
- General Hospital Tesanj
-
-
-
-
-
Gabrovo, Bulgarien, 5300
- Mhat Dr.Tota Venkova
-
Montana, Bulgarien, 3400
- Medical Center Hera EOOD
-
Plovdiv, Bulgarien, 4002
- UMHAT Kaspela
-
Rousse, Bulgarien, 7012
- Medical Center "Teodora"
-
Sofia, Bulgarien, 1510
- Medical Center Hera EOOD
-
Sofia, Bulgarien, 1113
- DCC 22 - Sofia
-
Sofia, Bulgarien, 1784
- Medical Center ''Synexus Sofia'' EOOD
-
Stara Zagora, Bulgarien, 6000
- University Hospital of Active Treatment Prof. Stoyan Kirkovich
-
Varna, Bulgarien, 9002
- MHAT"Sv.Anna-Varna"AD
-
-
Sofia-Grad
-
Sofia, Sofia-Grad, Bulgarien, 1233
- 5 th MHAT
-
Sofia, Sofia-Grad, Bulgarien, 1407
- Medical Center Excelsior
-
Sofia, Sofia-Grad, Bulgarien, 1431
- UMHAT St. Ekaterina
-
Sofia, Sofia-Grad, Bulgarien, 1612
- Comac Medical Ltd
-
-
-
-
-
Chongqing, China, 400038
- The Southwest Hospital of AMU
-
Shanghai, China, 200233
- Shanghai Sixth People's Hospital
-
Tianjin, China, 300052
- Tianjin Medical University General Hospital
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100034
- Peking University First Hospital
-
Beijing, Beijing Municipality, China, 100029
- China-Japan Friendship Hospital
-
Beijing, Beijing Municipality, China, 100730
- Beijing Hospital
-
Beijing, Beijing Municipality, China, 100020
- Beijing Chao-Yang Hospital, Capital Medical University
-
Beijing, Beijing Municipality, China, 100029
- Beijing An Zhen Hospital, Capital Medical University
-
-
Fujian
-
Fuzhou, Fujian, China, 350005
- The First Affiliated Hospital of Fujian Medical University
-
Xiamen, Fujian, China, 361003
- The First Affiliated Hospital of Xiamen University
-
Xiamen, Fujian, China, 361004
- Zhongshan Hospital Xiamen University
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Guangdong Provincial People's Hospital
-
Guangzhou, Guangdong, China, 510180
- Guangzhou First People's Hospital - Nephrology
-
Guangzhou, Guangdong, China, 510655
- The Third Affiliated Hospital, Sun Yat-sen University
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- The People's Hospital of Guangxi Zhuang Autonomous Region- Nephrology
-
-
Guizhou
-
Guiyang, Guizhou, China, 550004
- The Affliated Hospital of Guizhou Medical University
-
-
Hebei
-
Shijiazhuang, Hebei, China, 50004
- The Second Hospital of Hebei Medical University
-
-
Henan
-
Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou University (East Compus)
-
-
Hubei
-
Wuhan, Hubei, China
- The Central Hospital of Wuhan
-
-
Hunan
-
Changsha, Hunan, China, 410011
- The Second Xiangya Hospital of Central South University
-
Changsha, Hunan, China, 410013
- The Third Xiangya Hospital of Central South University
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210029
- Jiangsu Province Hospital/ The First Affiliated Hospital with Nanjing Medical University
-
Wuxi, Jiangsu, China, 214023
- Wuxi People's Hospital
-
-
Nei Mongol (mn)
-
Baotou, Nei Mongol (mn), China, 014010
- The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology
-
-
Ningxia
-
Yinchuan, Ningxia, China, 750004
- General Hospital of Ningxia Medical University
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710061
- The First Affiliated Hospital of Xi'an Jiaotong University
-
-
Shandong
-
Jinan, Shandong, China
- Shandong Provincial Hospital
-
Yantai, Shandong, China, 264000
- Yantai Yuhuangding Hospital(Base Cpmpus)
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200000
- Shanghai General Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610072
- Sichuan Academy of Medical Sciences
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Hangzhou, Zhejiang, China
- Zhejiang Provincial People's Hospital
-
Hangzhou, Zhejiang, China
- Zhejiang Hospital
-
Jinhua, Zhejiang, China, 321000
- Jinhua Central Hospital
-
Wenzhou, Zhejiang, China, 325000
- The First Affiliated Hospital of Wenzhou Medical University
-
-
-
-
-
Berlin, Deutschland, 12203
- Charité - Universitätsmedizin Berlin
-
Berlin, Deutschland, 10117
- Charité- Universitätsmedizin Berlin
-
Hanover, Deutschland, 30625
- Medizinische Hochschule Hannover
-
Jena, Deutschland, 07747
- Universitätsklinikum Jena
-
-
Baden-Wurttemberg
-
Villingen-Schwenningen, Baden-Wurttemberg, Deutschland, 78052
- Nephrologisches Zentrum Villingen-Schwenningen
-
-
North Rhine-Westphalia
-
Dortmund, North Rhine-Westphalia, Deutschland, 44137
- Diabeteszentrum DO
-
Düsseldorf, North Rhine-Westphalia, Deutschland, 23538
- DaVita Clinical Research Germany GmbH
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Deutschland, 55131
- Universitätsklinikum Mainz
-
-
-
-
-
Batumi, Georgia, 6010
- JSC "Evex Hospitals'
-
Tbilisi, Georgia, 0102
- Aleksandre Aladashvili Clinic LLC
-
Tbilisi, Georgia, 0144
- National Center of Urology Named after Laur Managadze
-
Tbilisi, Georgia, 0112
- LTD Israel-Georgian Medical Research Clinic Helsicore
-
Tbilisi, Georgia, 0114
- "Pineo Medical Ecosystem"LTD
-
Tbilisi, Georgia, 0119
- JSC German Clinic
-
Tbilisi, Georgia, 0159
- Bokhua Memorial Cardiovascular Centre
-
Tbilisi, Georgia, 0159
- Emergency Cardiology Center named by acad. G. Chapidze
-
Tbilisi, Georgia, 0159
- J.S.C."K.Eristavi National Center of Experimental and Clinical Surgery"
-
-
Adjara
-
Batumi, Adjara, Georgia, 6000
- LTD "High technology hospital MEDCENTER"
-
-
Kvemo Kartli
-
Marneuli, Kvemo Kartli, Georgia, 3000
- Ltd Marnecor
-
-
Shida Kartli
-
Gori, Shida Kartli, Georgia, 1400
- Ministry of Defence of Georgia LEPL Giorgi Abramishvili Military Hospital
-
-
-
-
-
Hong Kong, Hongkong
- Tung Wah Hospital
-
Hong Kong, Hongkong
- Queen Mary Hospital - Medicine
-
-
-
-
Central District
-
Petah Tikwa, Central District, Israel, 49100
- Rabin Medical Center
-
-
Northern District
-
Nazareth, Northern District, Israel, 16100
- Nazareth Hospital EMMS
-
-
-
-
Ontario
-
Toronto, Ontario, Kanada, M4C 5T2
- Dr. Stephen S. Chow Medicine Professional Corporation
-
Waterloo, Ontario, Kanada, N2T 0C1
- Clinical Research Solutions Incorporated
-
-
-
-
-
Split, Kroatien, 21000
- University Hospital Center Split
-
-
City of Zagreb
-
Zagreb, City of Zagreb, Kroatien, 10000
- University Hospital Centre Zagreb
-
-
Osjecko-baranjska Županija
-
Vinkovci, Osjecko-baranjska Županija, Kroatien, 32100
- Opca bolnica Vinkovci
-
-
-
-
-
Riga, Lettland
- P.Stradina Clinical University Hospital
-
-
Ogre
-
Ogre, Ogre, Lettland
- Dace Teterovska - Doctor's Practice
-
-
-
-
Kaunas County
-
Kaunas, Kaunas County, Litauen, LT-49449
- Saules seimos medicinos centras
-
-
-
-
Kelantan
-
Kota Bharu, Kelantan, Malaysia, 15586
- Hospital Raja Perempuan Zainab II
-
-
Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malaysia, 50586
- Hospital Kuala Lumpur
-
Kuala Lumpur, Kuala Lumpur, Malaysia, 59100
- University Malaya Medical Centre
-
-
Perak
-
Ipoh, Perak, Malaysia, 30450
- Hospital Raja Permaisuri Bainun
-
Seri Manjung, Perak, Malaysia, 32400
- Hospital Seri Manjung
-
-
-
-
-
Katowice, Polen, 40-040
- Synexus Polska Sp. z o.o.
-
Lodz, Polen, 90127
- Synexus Polska Sp. z. o.o.
-
Lodz, Polen, 92-213
- SP ZOZ Centralny Szpital Kliniczny UM w Lodzi
-
Lublin, Polen, 20954
- Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie
-
Poznan, Polen, 60-702
- Synexus Polska Sp. z o.o.
-
Warsaw, Polen, 02-672
- Synexus Polska Sp. z o.o.
-
Wroclaw, Polen, 51-685
- WroMedica I. Bielicka, A. Strzalkowska s.c.
-
-
Kuyavian-Pomeranian Voivodeship
-
Grudziądz, Kuyavian-Pomeranian Voivodeship, Polen, 86-300
- NZOZ Euromedica Sp. z o.o.
-
-
Lódzkie
-
Lodz, Lódzkie, Polen, 94-074
- Prywatny Gabinet Lekarski i Wizyty Lekarskie Jan Ruxer
-
-
-
-
-
Belgrade, Serbien, 11000
- Military Medical Academy
-
Belgrade, Serbien, 11000
- Zvezdara University Medical Center
-
Belgrade, Serbien
- MSB General hospital - Clinical Research Center
-
Kragujevac, Serbien, 33126-3422
- Clinical Center Kragujevac
-
-
Belgrade
-
Zemun, Belgrade, Serbien, 11080
- Clinical Hospital Centre Zemun
-
-
Nišavski Okrug
-
Niš, Nišavski Okrug, Serbien, 18000
- Clinical Centre Nis
-
-
Vojvodina
-
Novi Sad, Vojvodina, Serbien, 21000
- Clinical Center Vojvodina
-
-
-
-
-
Barcelona, Spanien, 8023
- Hospital Quironsalud Barcelona
-
Barcelona, Spanien, 08025
- FUNDACION PUIGVERT - Nephrology Department
-
Barcelona, Spanien, 8035
- Hospital de La Santa Creu i Sant Pau
-
Barcelona, Spanien, 8003
- Hospital del Mar
-
Granada, Spanien, 18014
- Hospital Universitario Virgen de las Nieves
-
Lugo, Spanien, 27880
- Hospital público da Mariña
-
Lugo, Spanien, 27880
- Hospital Ribera Polusa
-
Madrid, Spanien, 28040
- Hospital Universitario Fundación Jiménez Díaz
-
Valencia, Spanien, 46026
- Hospital Universitario Y Politécnico La Fe
-
-
Valenciana, Comunidad
-
Valencia, Valenciana, Comunidad, Spanien, 46014
- Consorcio Hospital General Universitario de Valencia
-
-
-
-
Free State
-
Bloemfontein, Free State, Südafrika, 9301
- Iatros International
-
-
Gauteng
-
Soweto, Gauteng, Südafrika, 2193
- Charlotte Maxeke Johannesburg Hospital
-
-
KwaZulu-Natal
-
Durban, KwaZulu-Natal, Südafrika, 4001
- Office of Gulam Hoosain Vally
-
-
Western Cape
-
Cape Town, Western Cape, Südafrika, 7530
- Tiervlei Trial Centre
-
Somerset West, Western Cape, Südafrika, 7130
- Dr J.M. Engelbrecht Trial Site
-
-
-
-
-
Seoul, Südkorea, 03080
- Seoul National University Hospital - Nephrology
-
-
Daejeon Gwang'yeogsi [Taejon-Kwangyokshi]
-
Daejeon, Daejeon Gwang'yeogsi [Taejon-Kwangyokshi], Südkorea, 35015
- Chungnam National University Hospital - Nephrology
-
-
Gyeonggido [Kyonggi-do]
-
Goyang-si, Gyeonggido [Kyonggi-do], Südkorea, 10444
- National Health Insurance Service Ilsan Hospital - Nephrology
-
-
Seoul Teugbyeolsi [Seoul-T'ukpyolshi]
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Südkorea, 6273
- Gangnam Severance Hospital, Yonsei University Health System - Internal Medicine
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Südkorea, 6351
- Samsung Medical Center - Nephrology
-
Seoul, Seoul Teugbyeolsi [Seoul-T'ukpyolshi], Südkorea, 6591
- The Catholic University of Korea, Seoul St. Mary's Hospital
-
-
-
-
-
Taichung, Taiwan, 406
- China Medical University Hospital - Nephrology - Taichung
-
Taipei, Taiwan, 110
- Taipei Medical University - Shuang Ho Hospital - Nephrology
-
Taoyuan, Taiwan, 33305
- Chang Gung Medical Foundation - LinKou Chang Gung Memorial Hospital - Nephrology
-
-
Taichung Municipality
-
Taichung, Taichung Municipality, Taiwan, 40705
- Taichung Veterans General Hospital - Nephrology
-
-
Taipei Special Muncipality
-
Taipei, Taipei Special Muncipality, Taiwan, 10002
- National Taiwan University Hospital - Nephrology
-
-
-
-
-
Prague, Tschechien, 140 21
- IKEM
-
Prague, Tschechien, 160 00
- Alaron s.r.o.
-
-
Praha 4
-
Prague, Praha 4, Tschechien, 149 00
- Nefrologie s.r.o.
-
-
Třebíč
-
Třebíč, Třebíč, Tschechien, 674 01
- Nemocnice Trebic, p.o.
-
-
-
-
-
Budapest, Ungarn, 1083
- Semmelweis Egyetem
-
Budapest, Ungarn, 1204
- Jahn Ferenc Dél-Pesti Kórház és Rendelőintézet
-
Kaposvár, Ungarn, H-7400
- Somogy Megyei Kaposi Mór Oktató Kórház
-
-
Baranya
-
Pécs, Baranya, Ungarn, 7624
- Coromed-Smo Kft.
-
-
Borsod-Abauj Zemplen county
-
Miskolc, Borsod-Abauj Zemplen county, Ungarn, 3530
- IPR Hungary Kft.
-
-
Csongrád megye
-
Szeged, Csongrád megye, Ungarn, 6725
- Sonocor Egészségügyi Szolgáltató Kft.
-
-
Győr-Moson-Sopron
-
Mosonmagyaróvár, Győr-Moson-Sopron, Ungarn, 7624
- TaNa Med Kft
-
-
Heves County
-
Hatvan, Heves County, Ungarn, H-3000
- BKS Research
-
-
Pest County
-
Kistarcsa, Pest County, Ungarn, 2143
- Kistarcsai Flor Ferenc Korhaz
-
-
Veszprém City
-
Balatonfüred, Veszprém City, Ungarn, 8230
- DRC Gyógyszervizsgáló Központ Kft.
-
-
-
-
Alabama
-
Foley, Alabama, Vereinigte Staaten, 36535
- G & L Research, LLC
-
Huntsville, Alabama, Vereinigte Staaten, 35805
- Apogee Clinical Research, LLC
-
-
Arizona
-
Mesa, Arizona, Vereinigte Staaten, 85210
- Aventiv Research, Inc
-
-
California
-
Beverly Hills, California, Vereinigte Staaten, 90211-2285
- National Heart Institute
-
Granada Hills, California, Vereinigte Staaten, 91344
- Amicis Research Center
-
Granada Hills, California, Vereinigte Staaten, 91324
- Amicis Research Center (Valencia)
-
Lancaster, California, Vereinigte Staaten, 93534
- Amicis Research Center
-
Northridge, California, Vereinigte Staaten, 91325
- Renal Consultants Medical Group - Granada Hills
-
South Gate, California, Vereinigte Staaten, 90280
- United Clinical Research and Innovations
-
Vacaville, California, Vereinigte Staaten, 95687-3557
- Solano Kidney Care
-
Victorville, California, Vereinigte Staaten, 92392
- Desert Cities Dialysis - Amethyst
-
Victorville, California, Vereinigte Staaten, 92395
- Kidney and Hypertension Center
-
-
Connecticut
-
Bloomfield, Connecticut, Vereinigte Staaten, 06002
- Davita Clinical Research-Hartford
-
-
Florida
-
Bradenton, Florida, Vereinigte Staaten, 34208
- Synergy Healthcare
-
Miami, Florida, Vereinigte Staaten, 33155
- Allied Biomedical Research Institute
-
Miami, Florida, Vereinigte Staaten, 33126
- LCC Medical Research
-
Miami, Florida, Vereinigte Staaten, 33032-8225
- Homestead Associates in Research, Inc
-
Miami, Florida, Vereinigte Staaten, 33126-3422
- Total Research Group
-
Miami, Florida, Vereinigte Staaten, 33144
- Oceane 7 Medical&Research Center, Inc.
-
Miami, Florida, Vereinigte Staaten, 33166
- South Florida Research Phase I-Iv, Inc.
-
Miami Lakes, Florida, Vereinigte Staaten, 33014
- Inpatient Research Clinic, LLC
-
Miami Lakes, Florida, Vereinigte Staaten, 33014-5602
- San Marcus Research Clinic, Inc.
-
Naples, Florida, Vereinigte Staaten, 34104
- New Generation Of Medical Research
-
Ocala, Florida, Vereinigte Staaten, 34471
- Sarkis Clinical
-
Orlando, Florida, Vereinigte Staaten, 32808
- Omega Research Orlando, LLC
-
Tampa, Florida, Vereinigte Staaten, 33603
- Genesis Clinical Research
-
Tampa, Florida, Vereinigte Staaten, 33604
- Santos Research Center CORP
-
-
Georgia
-
Atlanta, Georgia, Vereinigte Staaten, 30342
- Fides Clinical Research
-
Augusta, Georgia, Vereinigte Staaten, 30904
- Southeastern Clinical Research Institute, LLC
-
Columbus, Georgia, Vereinigte Staaten, 31904-3650
- Columbus Associates LLC
-
Macon, Georgia, Vereinigte Staaten, 31201-6863
- Central Georgia Kidney Specialists
-
-
Illinois
-
Gurney, Illinois, Vereinigte Staaten, 60031
- Clinical Investigation Specialists, Inc.
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02114
- Massachusetts General Hospital (MGH) - Renal Associates Clinic
-
-
Minnesota
-
Edina, Minnesota, Vereinigte Staaten, 55435-2129
- InterMed Consultants
-
-
Missouri
-
Hazelwood, Missouri, Vereinigte Staaten, 63042
- Healthcare Research Network
-
Kansas City, Missouri, Vereinigte Staaten, 64111-5964
- Clinical Research Consultants
-
St Louis, Missouri, Vereinigte Staaten, 63136-6111
- St. Louis Heart and Vascular, P.C. (SLHV) - Christian Hospital Office
-
-
Nevada
-
Las Vegas, Nevada, Vereinigte Staaten, 89102-1682
- Healor Primary Care /CCT Research
-
Las Vegas, Nevada, Vereinigte Staaten, 89128
- DaVita Clinical Research (Nevada)
-
-
New York
-
Jamaica, New York, Vereinigte Staaten, 11432
- NYC Health + Hospitals / Queens - Diabetes Center of Excellence
-
Ridgewood, New York, Vereinigte Staaten, 11385
- Mattoo & Bhat Medical Associates, PC
-
The Bronx, New York, Vereinigte Staaten, 10461-1900
- Albert Einstein's College of Medicine
-
The Bronx, New York, Vereinigte Staaten, 10461-2710
- Kidney Medical Associates, PLLC
-
-
North Carolina
-
Asheville, North Carolina, Vereinigte Staaten, 28801-4104
- Mountain Kidney & Hypertension Associates (MKHA), P.A - Asheville
-
Greenville, North Carolina, Vereinigte Staaten, 27834
- Physicians East, PA
-
Jacksonville, North Carolina, Vereinigte Staaten, 28546
- Eastern Nephrology Associates - Jacksonville
-
New Bern, North Carolina, Vereinigte Staaten, 28562-5200
- Eastern Nephrology Associates - New Bern
-
Raleigh, North Carolina, Vereinigte Staaten, 27609-7511
- North Carolina Nephrology P.A.
-
Winston-Salem, North Carolina, Vereinigte Staaten, 27103-7108
- Brookview Hills Research Associates, LLC
-
-
Ohio
-
Dayton, Ohio, Vereinigte Staaten, 45439
- Providence Health Partners-Center for Clinical Research
-
-
South Carolina
-
Columbia, South Carolina, Vereinigte Staaten, 29203-6476
- Columbia Nephrology Associates, PA
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37923-3624
- Knoxville Kidney Center, PLLC
-
-
Texas
-
Austin, Texas, Vereinigte Staaten, 78503
- Gamma Clinical Research Institute
-
El Paso, Texas, Vereinigte Staaten, 79925
- Davita Clinical Research El Paso
-
El Paso, Texas, Vereinigte Staaten, 79935
- Kidney Consultants of El Paso, P.A.
-
Houston, Texas, Vereinigte Staaten, 77099
- Pioneer Research Solutions, Inc.
-
Houston, Texas, Vereinigte Staaten, 77004
- DaVita Clinical Research Houston
-
San Antonio, Texas, Vereinigte Staaten, 78251
- DaVita Clinical Research
-
San Antonio, Texas, Vereinigte Staaten, 78212-4738
- Clinical Advancement Center, PLLC
-
San Antonio, Texas, Vereinigte Staaten, 78229-3342
- Urology San Antonio - North Central
-
The Woodlands, Texas, Vereinigte Staaten, 77384
- Kidney Specialists of North Houston, PLLC
-
-
Virginia
-
Norfolk, Virginia, Vereinigte Staaten, 23502
- Davita Norfolk Square
-
Richmond, Virginia, Vereinigte Staaten, 23219
- Dominion Medical Associates, Inc.
-
-
Wisconsin
-
Kenosha, Wisconsin, Vereinigte Staaten, 53142
- Clinical Investigation Specialists
-
Wauwatosa, Wisconsin, Vereinigte Staaten, 53226
- Milwaukee Nephrologists, SC (Rich)
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
-
Body mass index (BMI) must be ≥19 to <45 kg/m^2 at the Screening Visit
-
Participant must have uncontrolled hypertension defined as meeting both of the following criteria:
- The participant has a resting seated trough cuff SBP ≥140 mm Hg at the Screening Visit (Visit 1), and at the start (Visit 2) and end (Visit 3) of the Run-In Period
- The participant is taking 2 or more antihypertensive medications that have been titrated upward as tolerated to hypertension target doses per local SoC and have been stable (i.e., without any dose adjustments) from 4 weeks before the Screening Visit (Visit 1) through the end of the Run-In Period (Visit 3)
-
The participant must have Stage 3b (eGFR [EPI] ≥30 and ≤44 mL/min/1.73 m^2) or Stage 4 (eGFR [EPI] ≥15 and <30 mL/min/1.73 m^2) CKD.
Exclusion Criteria:
- Participant has a resting seated trough cuff SBP ≥180 mm Hg at the Screening Visit (Visit 1) or at the start (Visit 2) or end (Visit 3) of the Run-In Period
- Participant has a serum potassium level >4.8 mmol/L during the Screening or Run-In Periods
- Participant has had a serum potassium level >5.6 mmol/L within 2 weeks before the Screening Visit (Visit 1)
- Participant has been hospitalized for hyperkalemia within the 3 months before the Randomization Visit (Visit 3)
- Participant was not compliant with taking placebo during the Run-in Period or participant was not compliant with background antihypertensive medications during the Run-in Period as assessed at the Randomization Visit (Visit 3)
- Participant has taken an mineralocorticoid receptor antagonist (MRA), a potassium-sparing diuretic, or chronic potassium supplements during the 4 weeks before the Screening Visit (Visit 1)
- Participant has taken potassium binders for the treatment of hyperkalemia during the 3 months before the Screening Visit (Visit 1)
- Participant has taken a strong cytochrome P450 (CYP) CYP3A4 inducer or strong CYP3A4 inhibitor during the 7 days before the Randomization Visit (Visit 3)
- Participant has taken a prohibited traditional Chinese medication during the 28 days prior to Screening Visit (Visit 1).
- Participant was administered any other investigational product within 4 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit (Visit 1).
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Placebo-Komparator: Placebo
Open-label Placebo Run-In Period: All eligible participants will receive matching placebo, for approximately 2 weeks, during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive matching placebo, from week 2 thru week 24 during the Double-blind treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. |
Participants will orally receive placebo matching to KBP-5074 tablets QD. |
|
Experimental: KBP-5074
Open-label Placebo Run-In period: All eligible participants will receive matching placebo, for approximately 2 weeks during the Open-label placebo Run-In period. Double-blind Treatment Period: All eligible participants will receive KBP-5074, from week 2 thru week 24 during the Double-blind Treatment Period Open-label Treatment Period: All eligible participants will receive KBP-5074, from week 24 thru week 48 during the Open label Treatment Period Randomized Double-blind Withdrawal Period: All eligible participants will be randomized to either continue their current KBP-5074 dose at the end of the Open-Label Treatment Period or receive matching placebo from week 48 thru week 52. Follow up Period: All participants will discontinue matching placebo/KBP-5074 and be followed for safety until end of study visit from week 52 to week 56. |
Participants will orally receive KBP-5074 tablets, from 0.25 mg to a maximum dose of 0.5-mg QD. |
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Seated Trough Cuff Systolic Blood Pressure (SBP) From Baseline to Week 12
Zeitfenster: From baseline to Week 12
|
Efficacy of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for KBP-5074 dose regimen compared to placebo, was evaluated. |
From baseline to Week 12
|
|
Change in Seated Trough Cuff SBP From Week 48 to Week 52
Zeitfenster: From Week 48 to Week 52
|
Durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP for the KBP-5074 dose regimen compared to placebo, was evaluated. |
From Week 48 to Week 52
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in Seated Trough Cuff SBP From Baseline to Week 24
Zeitfenster: From baseline to Week 24
|
Efficacy and durability of KBP-5074 in reducing SBP by assessing change in seated trough cuff SBP, were evaluated. |
From baseline to Week 24
|
|
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 12
Zeitfenster: From baseline to Week 12
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP, was evaluated. |
From baseline to Week 12
|
|
Changes in Urinary Albumin: Creatinine Ratio (UACR) From Baseline to Week 12 for Participants With UACR ≥30 mg/g at Baseline
Zeitfenster: From baseline to Week 12
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. |
From baseline to Week 12
|
|
Percentage Changes in UACR From Baseline to Week 12 and Week 24 for Participants With UACR ≥30 mg/g at Baseline
Zeitfenster: From baseline to Week 12 and Week 24
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From baseline to Week 12 and Week 24
|
|
Changes in Seated Trough Cuff Diastolic Blood Pressure (DBP) From Baseline to Week 24
Zeitfenster: From baseline to Week 24
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated. |
From baseline to Week 24
|
|
Changes in Seated Trough Cuff DBP From Baseline to Week 48
Zeitfenster: From baseline to Week 48
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff SBP was evaluated. |
From baseline to Week 48
|
|
Changes in Seated Trough Cuff SBP From Baseline to Week 48
Zeitfenster: From baseline to Week 48
|
Effect of KBP-5074 on SBP by assessing change in seated trough cuff SBP was evaluated. |
From baseline to Week 48
|
|
Changes in UACR From Baseline to Week 24 for Participants With UACR ≥30 mg/g at Baseline
Zeitfenster: From baseline to Week 24
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g at baseline was evaluated. |
From baseline to Week 24
|
|
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Zeitfenster: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Macroalbuminuria
Zeitfenster: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Change in Seated Trough Cuff DBP From Week 48 to Week 52
Zeitfenster: From Week 48 to Week 52
|
Effect of KBP-5074 on DBP by assessing change in seated trough cuff DBP was evaluated. |
From Week 48 to Week 52
|
|
Change in UACR From Week 48 to Week 52 for Participants With UACR ≥30 mg/g at Baseline
Zeitfenster: Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With UACR ≥30 mg/g at Baseline
Zeitfenster: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing percentage changes in UACR for participants with UACR ≥30 mg/g was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Zeitfenster: Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
|
The safety and tolerability of KBP-5074 was evaluated. A treatment emergent adverse event (TEAE) was defined as any AE with onset during or after first dose and before 4 weeks after last dose of study drug, or any preexisting AE/condition that worsened during this period. Selected TEAEs include Hyperkalemia, Hypertension, Hypotension, and eGFR Decrease. |
Until end of study (EOS) (Week 56) or Unscheduled visit or end of treatment or early termination (up to 32 months)
|
|
Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Zeitfenster: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Percentage Changes in UACR From Baseline to Week 12, Week 24, and Week 48 in Participants With Microalbuminuria
Zeitfenster: From baseline to Week 12, Week 24, and Week 48
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline was evaluated. |
From baseline to Week 12, Week 24, and Week 48
|
|
Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Zeitfenster: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline, was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With Microalbuminuria
Zeitfenster: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with microalbuminuria (defined as UACR ≥30 and <300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Zeitfenster: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
|
Percentage Change in UACR From Week 48 to Week 52 in Participants With Macroalbuminuria
Zeitfenster: From Week 48 to Week 52
|
Effect of KBP-5074 on UACR by assessing changes in UACR for participants with macroalbuminuria (defined as UACR ≥300 mg/g) at baseline was evaluated. Here, overall number of participants analyzed field represents the number of participants assessed for this particular outcome measure at indicated time frame. |
From Week 48 to Week 52
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Urogenitale Erkrankungen
- Gefäßerkrankungen
- Herz-Kreislauf-Erkrankungen
- Pathologische Prozesse
- Männliche Urogenitalerkrankungen
- Nierenerkrankungen
- Urologische Erkrankungen
- Weibliche Urogenitalerkrankungen
- Weibliche Urogenitalerkrankungen und Schwangerschaftskomplikationen
- Chronische Erkrankung
- Krankheitsattribute
- Niereninsuffizienz
- Pathologische Zustände, Anzeichen und Symptome
- Hypertonie
- Niereninsuffizienz, chronisch
- KBP-5074
Andere Studien-ID-Nummern
- KBP5074-3-001
- 2021-003636-88 (EudraCT-Nummer)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .